Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries

• Status: Unknown status
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The present clinical trial randomized will be to assess the link between the different haplotypes of CYP2C8 and CYP2C9 genes and the clinical efficacy of ibuprofen after lower third molar extractions. Onset, duration of postoperative analgesia, duration of anesthetic action on soft tissues, intraoperative bleeding, hemodynamic parameters, postoperative mouth opening and wound healing at the 7th postoperative day were evaluated. For this purpose, 200 healthy volunteers underwent removal of one lower third molar, under local anesthesia with articaine 4% (1:200,000 adrenaline) will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sao Paulo
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Ibuprofen

Criteria

Inclusion Criteria:

• Need of lower third molar surgeries

Exclusion Criteria:

• Presence of systemic diseases;

• Presence of local inflammation and/or infection;

• Any history of allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration;

• Cardiovascular, kidney or hepatic diseases;

• Patients who are making use of antidepressants, diuretics or anticoagulants;

• Asthma and allergy to aspirin, ibuprofen or any other nonsteroidal antiinflammatory drug;

• Regular use of any nonsteroidal antiinflammatory drug,

• Pregnancy or breast feeding.